In patients, with estrogen receptor (ER)-positive and human epidermal growth factor receptor 2 (HER2)-negative metastatic disease, the choice of treatment depends on multiple factors, including prior treatment, toxicity, performance status (PS), comorbidity, and patient preference. The gene discussed is ESR1; the disease is metastatic neoplasm.